Prognostic value of LSC burden after 2 cycles of chemotherapy. Kaplan-Meier curves of (A) OS, (C) CIR after C2. The overall group in A and C is divided into patients with LSC^pos and LSC^neg with the cut-off of 0.00000% CD34⁺CD38^–LSC⁺ population. B and D show multivariate analysis adjusted for LSC status at diagnosis, age, AML type, ELN2017 risk group, WBCs at diagnosis, and last treatment before reaching CR (only CIR) of (B) OS (Cox regression) and (D) CIR (Fine and Gray subdistribution hazard regression).